Welcome to the e-CCO Library!

P494: A serum metabolite panel predicts Crohn’s disease relapse in patients discontinuing infliximab and continuing antimetabolite therapy: sub-analysis of the SPARE Trial.
Year: 2022
Source: ECCO'22
Authors: Radford-Smith, D.(1);Satsangi, J.(2);Louis, E.(3);Laharie, D.(4);Ding, N.(5);Siegmund, B.(6);D'Haens, G.(7);Erik, H.(8);Yates, A.(9);Anthony, D.(1);Colombel, J.F.(10);Probert, F.(9);
Created: Friday, 11 February 2022, 3:56 PM
P494: Can Patients Monitor Response To Ustekinumab In The Real World?
Year: 2021
Source: ECCO'21 Virtual
Authors: Walsh, A.J.(1);Matini, L.(1);Kormilitzin, A.(2);Wilson, J.(1);Lyden, S.(1);Al-Hillawi, L.(1);Kantschuster, R.(1);White, L.(1);Payton, S.(1);Brain, O.(1);Palmer, R.(1);Ambrose, T.(1);Satsangi, J.(1);Travis, S.P.L.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P494: Impact of early optimization of ustekinumab on mid-term targets in severe Crohn's disease: THE MUST study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Abdelmoula, A.(1)*;Chateau, T.(2);Hupe, M.(2);Boschetti, G.(3);Roblin, X.(4);Nancey, S.(3);Mathieu, N.(2);
Created: Friday, 14 July 2023, 11:05 AM
P494: Monocytic TNF production predicts response to infliximab treatment in Crohn’s disease but not ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Jessen1,2*, D. Lissner1, E. Sonnenberg1, M. Schumann1, F. Schmidt1, A. Kühl1, B. Siegmund1

Created: Thursday, 21 February 2019, 9:14 AM
P494: Multicentre cohort study to evaluate the need for re-intervention following multimodal treatment in Crohn's disease with perianal fistula
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sebastian S.*1,2, Black C.2, Pugliese D.3, Armuzzi A.3, Sahnan K.4, Elkady S.M.4, Katsanos K.H.5, Christodoulou D.K.5, Selinger C.6, Maconi G.7, Fiorino G.8, Kopylov U.9, Davidov Y.9, Bosca-Watts M.M.10, Ellul P.11, Muscat M.11, Karmiris K.12, Fearnhead N.S.13, Allgar V.14, Hart A.L.4, Ben-Horin S.9, Danese S.8

Created: Wednesday, 20 February 2019, 10:36 AM
P494: Phenotypic analysis revealed features of disease severity in familial versus sporadic cases of inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. Maurizi, M. Giannotta*, V. Almerigogna, S. Biagini, A. Cozzi, G. Macrì, M. Milla

Created: Friday, 22 February 2019, 9:49 AM
P494: Regional survey on satisfaction with healthcare in inflammatory bowel disease patients
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

V. Borzan1,2, V. Orsic Fric*1,2, B. Borzan2

Created: Friday, 22 February 2019, 9:41 AM
P495 Usefulness of a capsule endoscopy scoring system in understanding the disease state of Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Omori, H. Kambayashi, S. Murasugi, A. Ito, M. Yonezawa, K. Tokushige

Created: Thursday, 30 January 2020, 10:12 AM
P495: Biosimilar infliximab is effective and safe in inflammatory bowel disease patients naïve to anti-TNF therapy: a tertiary centre experience
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Bortlik*1, 2, M. Kolar1, D. Duricova1, 3, K. Malickova4, V. Hruba1, N. Machkova1, K. Mitrova1, M. Lukas1, M. Lukas1, 4

Created: Friday, 22 February 2019, 9:49 AM
P495: Does drug level monitoring help us to understand the mechanism behind the superiority of combo therapy in inflammatory bowel diseases?
Year: 2018
Source: ECCO '18 Vienna
Authors:

A. Fábián1*, K. Szántó1, A.L. Szíjártó2, R. Bor1, A. Bálint1, K. Farkas1, Á. Milassin1, M. Rutka1, Z. Szepes1, I. Földesi3, D. Kata3, Z.A. Mezei4, S. Lovas5, K. Palatka5, T. Molnár1

Created: Thursday, 21 February 2019, 9:14 AM
P495: Intensified infliximab rescue therapy for acute severe ulcerative colitis does not improve long term colectomy-free survival
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Al Khoury A.*1, Chao C.-y.2, Aruljothy A.2, Wyse J.3, Bessissow T.2

Created: Wednesday, 20 February 2019, 10:36 AM
P495: Perianal fistula closure in patients receiving ustekinumab: Results from the SEAVUE and STARDUST trials
Year: 2022
Source: ECCO'22
Authors: Peyrin-Biroulet, L.(1);Panaccione, R.(2);Gasink, C.(3);Hoops, T.(3);Izanec, J.L.(3);Ma, T.(4);Nazar, M.(5);Bravata, I.(6);Lahaye, M.(7);Irving, P.M.(8);Loftus, E.V.(9);Danese, S.(10);Sands, B.E.(11);
Created: Friday, 11 February 2022, 3:56 PM
P495: Spacing the administration interval of anti-TNF agents: a valid strategy for patients with inflammatory bowel disease?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

P. Torres*1,2, L. Núñez3, A. Aguilar1, M. Mañosa1,4, F. Mesonero3, F. Cañete1,4, M. Calafat1, C. Fernandez3, E. Cabré1,4, A. López-Sanromán3, E. Domènech1,4

Created: Friday, 22 February 2019, 9:41 AM
P495: The interplay of biopsychosocial factors and quality of life in Inflammatory Bowel Diseases: a network analysis
Year: 2021
Source: ECCO'21 Virtual
Authors: Knödler, L.L.(1);Thomann, A.(1);Karthikeyan, S.(2);Atanasova, K.(3);Bernstein, C.(4);Ebert, M.(1);Lis, S.(3);Reindl, W.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P495: Vedolizumab trough concentrations and histological remission in Ulcerative Colitis: Results from the LOVE-UC study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Hanzel, J.(1)*;Baert, F.(2);Löwenberg, M.(3);Ferrante, M.(4);Bossuyt, P.(5);Hoentjen, F.(6);Franchimont, D.(7);Palatka, K.(8);Peeters, H.(9);Mookhoek, A.(10);de Hertogh, G.(11);Clasquin, E.(3);Vermeire, S.(4);D'Haens, G.(3);
Created: Friday, 14 July 2023, 11:05 AM
P496 Feasibility and safety of single incision laparoscopic surgery for patients with complex Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y. LI, B. Liu, D. Yao, L. Zheng, Z. Zhou, Y. Huang, Y. Duan

Created: Thursday, 30 January 2020, 10:12 AM
P496: Adalimumab treatment reduces extraintestinal manifestations in patients with moderate-to-severe Crohn’s disease: a pooled analysis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

E. J. Louis*1, R. Löfberg2, W. Reinisch3, D. Schwartz4, J.-F. Maa5, S. Berg5, B. Huang5, A. W. Wang5, A. M. Robinson5, B. Pappalardo5

Created: Friday, 22 February 2019, 9:49 AM
P496: Antenatal thiopurine exposure in women with IBD is associated with intrahepatic cholestasis of pregnancy
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Rosiou, K.(1)*;Broglio, G.(1,2);Lever, G.(1);Chiu, C.M.(1);Stocker, L.J.(3);Chipeta, H.(3);Glanville, T.(3);Selinger, C.P.(1);
Created: Friday, 14 July 2023, 11:05 AM
P496: Efficacy and safety of elective switching of inflammatory bowel disease patients from intravenous to subcutaneous infliximab (IFX): a multi-centre cohort study
Year: 2021
Source: ECCO'21 Virtual
Authors: Smith, P.J.(1);Storey, D.(1);Gregg, B.(1);Critchley, L.(1);Stenson, J.(1);Kneebone, A.(1);Rimmer, T.(1);Burke, S.(1);Hussain, S.(2);Teoh, W.Y.(2);Vazeille, S.(2);Serna, S.(3);Bond, A.(1);Steel, A.(1);Dibb, M.(1);Collins, P.(1);Derbyshire, E.(1);Bodger, K.(1);Probert, C.(1);Verma, A.(3);Subramanian, S.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P496: Efficacy and safety of ustekinumab for chronic antibiotic refractory pouchitis: A Belgian open-label multicentre pilot study
Year: 2022
Source: ECCO'22
Authors: Outtier, A.(1);Louis, E.(2);Dewit, O.(3);Schops, G.(1);Verstockt, B.(1);Sabino, J.(1);Vermeire, S.(1);Ferrante, M.(1);
Created: Friday, 11 February 2022, 3:56 PM